Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice

Journal of Lipid Research

Volumn 51, Issue 6, 2010, Pages 1464-1470

  Taneja, Deepa ^b   Thompson, Joel ^a,b   Wilson, Patricia ^a,b   Brandewie, Katie ^b   Schaefer, Liliana ^c   Mitchell, Bonnie ^b   Tannock, Lisa R ^a,b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Apolipoprotein B; Diabetes; Mesangial matrix

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CHOLESTEROL INTAKE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FEMALE; HYPERLIPIDEMIA; KIDNEY HYPERTROPHY; KIDNEY INJURY; LIPID METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; URINARY EXCRETION;

ANIMALS; CHOLESTEROL; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HYPERLIPIDEMIAS; KIDNEY; MICE; SURVIVAL ANALYSIS;

EID: 77952688396     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M002972     Document Type: Article

References (32)

1. Kamanna, V. S., R. Pai, D. D. Roh, and M. A. Kirschenbaum. 1996. Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation. Lab. Invest. 74: 1067-1079.
2. Pai, R., M. A. Kirschenbaum, and V. S. Kamanna. 1995. Low-density lipoprotein stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells. Kidney Int. 48: 1254-1262.
3. Chana, R. S., D. C. Wheeler, G. J. Thomas, J. D. Williams, and M. Davies. 2000. Low-density lipoprotein stimulates mesangial cell proteoglycan and hyaluronan synthesis. Nephrol. Dial. Transplant. 15: 167-172.
4. Kamanna, V. S. 2002. Low density lipoproteins and mitogenic signal transduction processes: role in the pathogenesis of renal disease. Histol. Histopathol. 17: 497-505.
5. Lee, H. S., B. C. Kim, H. K. Hong, and Y. S. Kim. 1999. LDL stimulates collagen mRNA synthesis in mesangial cells through induction of PKC and TGF-beta expression. Am. J. Physiol. 277: F369-F376.
6. Kamanna, V. S., B. V. Bassa, and S. H. Ganji. 2008. Low density lipoproteins transactivate EGF receptor: role in mesangial cell proliferation. Life Sci. 83: 595-601.
7. Ravid, M., D. Brosh, D. Ravid-Safran, Z. Levy, and R. Rachmani. 1998. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch. Intern. Med. 158: 998-1004.
8. Samuelsson, O., H. Mulec, C. Knight-Gibson, P. O. Attman, B. Kron, R. Larsson, L. Weiss, H. Wedel, and P. Alaupovic. 1997. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol. Dial. Transplant. 12: 1908-1915. (Pubitemid 27379464)
9. Cases, A., and E. Coll. 2005. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int. Suppl. (99): S87-S93.
10. Sukhija, R., Z. Bursac, P. Kakar, L. Fink, C. Fort, S. Satwani, W. S. Aronow, D. Bansal, and J. L. Mehta. 2008. Effect of statins on the development of renal dysfunction. Am. J. Cardiol. 101: 975-979.
11. Fujii, M., T. Inoguchi, Y. Maeda, S. Sasaki, F. Sawada, R. Saito, K. Kobayashi, H. Sumimoto, and R. Takayanagi. 2007. Pitavastatin ameliorates albuminuria and renal mesangial expansion by down-regulating NOX4 in db/db mice. Kidney Int. 72: 473-480.
12. Ivanovski, O., D. Szumilak, T. Nguyen-Khoa, I. G. Nikolov, N. Joki, N. Mothu, J. Maizel, R. Westenfeld, M. Ketteler, B. Lacour, et al. 2008. Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure. J. Urol. 179: 1631-1636.
13. Sharyo, S., N. Yokota-Ikeda, M. Mori, K. Kumagai, K. Uchida, K. Ito, M. J. Burne-Taney, H. Rabb, and M. Ikeda. 2008. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int. 74: 577-584.
14. Zadelaar, S., R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra. 2007. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 27: 1706-1721. (Pubitemid 47207165)
15. Renard, C. B., F. Kramer, F. Johansson, N. Lamharzi, L. R. Tannock, M. G. Herrath, A. Chait, and K. E. Bornfeldt. 2004. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest. 114: 659-668.
16. Taneda, S., J. W. Pippin, E. H. Sage, K. L. Hudkins, Y. Takeuchi, W. G. Couser, and C. E. Alpers. 2003. Amelioration of diabetic nephropathy in SPARC-null mice. J. Am. Soc. Nephrol. 14: 968-980.
17. Muhlfeld, A. S., M. W. Spencer, K. L. Hudkins, E. Kirk, R. C. LeBoeuf, and C. E. Alpers. 2004. Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice. Kidney Int. 66: 1393-1402.
18. Spencer, M. W., A. S. Muhlfeld, S. Segerer, K. L. Hudkins, E. Kirk, R. C. LeBoeuf, and C. E. Alpers. 2004. Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice. Am. J. Nephrol. 24: 20-31.
19. Wen, M., S. Segerer, M. Dantas, P. A. Brown, K. L. Hudkins, T. Goodpaster, E. Kirk, R. C. LeBoeuf, and C. E. Alpers. 2002. Renal injury in apolipoprotein E-deficient mice. Lab. Invest. 82: 999-1006.
20. Daugherty, A., D. L. Rateri, H. Lu, T. Inagami, and L. A. Cassis. 2004. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation. 110: 3849-3857.
21. Huang, F., J. C. Thompson, P. G. Wilson, H. H. Aung, J. C. Rutledge, and L. R. Tannock. 2008. Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J. Lipid Res. 49: 521-530.
22. Gurley, S. B., S. E. Clare, K. P. Snow, A. Hu, T. W. Meyer, and T. M. Coffman. 2006. Impact of genetic background on nephropathy in diabetic mice. Am. J. Physiol. Renal Physiol. 290: F214-F222.
23. Qi, Z., H. Fujita, J. Jin, L. S. Davis, Y. Wang, A. B. Fogo, and M. D. Breyer. 2005. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes. 54: 2628-2637.
24. Samuelsson, O., P. O. Attman, C. Knight-Gibson, R. Larsson, H. Mulec, L. Weiss, and P. Alaupovic. 1998. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J. Am. Soc. Nephrol. 9: 1482-1488.
25. Samuelsson, O., M. Aurell, C. Knight-Gibson, P. Alaupovic, and P. O. Attman. 1993. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron. 63: 279-285. (Pubitemid 23082068)
26. Manttari, M., E. Tiula, T. Alikoski, and V. Manninen. 1995. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 26: 670-675.
27. Muntner, P., J. Coresh, J. C. Smith, J. Eckfeldt, and M. J. Klag. 2000. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 58: 293-301. (Pubitemid 30429874)
28. Lee, H. S., and Y. S. Kim. 1998. Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int. 54: 848-856. (Pubitemid 28397402)
29. Takemura, T., K. Yoshioka, N. Aya, K. Murakami, A. Matumoto, H. Itakura, T. Kodama, H. Suzuki, and S. Maki. 1993. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int. 43: 918-927.
30. Lee, H. S., J. S. Lee, H. I. Koh, and K. W. Ko. 1991. Intraglomerular lipid deposition in routine biopsies. Clin. Nephrol. 36: 67-75.
31. Sato, H., S. Suzuki, H. Kobayashi, S. Ogino, A. Inomata, and M. Arakawa. 1991. Immunohistological localization of apolipoproteins in the glomeruli in renal disease: specifically apoB and apoE. Clin. Nephrol. 36: 127-133.
32. Sandhu, S., N. Wiebe, L. F. Fried, and M. Tonelli. 2006. Statins for improving renal outcomes: a meta-analysis. J. Am. Soc. Nephrol. 17: 2006-2016.